Similarly, in a retrospective study including 1,118 patients treated with various neoadjuvant chemotherapeutic regimes Liedke et al. found equally high pCR rates in ER+/HER2+ and ER-/HER2- carcinomas (21% vs. 22%; ER+/HER2-: 5%, ER-/HER2+: 31%). The gene discussed is ESR1; the disease is carcinoma.